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Accepted 23 December 2013Autoimmune progesterone dermatitis (APD) is a rare autoim-
mune response to endogenous progesterone, characterized by cy-
clic cutaneous and mucosal lesions at the end of the luteal phase
when progesterone levels are elevated. These lesions usually
disappear 1e2 days after menstruation ceases [1]. The clinical
presentation of APD can vary in severity from urticaria to
anaphylaxis [2].We herein report three cases of APD and review the
current literature with regard to its clinical features, pathogenesis,
diagnosis, and treatment options.
A 38-year-old woman was admitted to the dermatology clinic
with a complaint of intermittent rash on her body for 3 years. The
recent lesions on her face and neck appeared 1 week before her
admission. Physical examination revealed erythematous papules in
the V region of the neck and edema of the face with urticarial
appearance (Fig. 1). She had no remarkable medical history. After a
detailed discussion with the patient, it was understood that these
lesions occurred 3 days before her menses and ended when the
menstruation ceased. She was investigated by an allergist for a
possible autoimmune hypersensitivity caused by increased levels of
progesterone. An intradermal testing with 50 mg/mL progesterone
was performed, which conﬁrmed the clinical diagnosis. Normal
saline was used as a negative control. Fifteen minutes after an in-
tradermal injection of the progesterone solution, an immediate
reactionwas observed (i.e., a 9-mmwheal was noted; Fig. 2). Based
on this result, the patient was diagnosedwith APD andwas referred
to a gynecologist. The patient was evaluated in the gynecology
clinic. She reported 28-day menstrual cycles and had experienced
skin lesions during every premenstrual period in the last 3 years.* Corresponding author. Department of Obstetrics and Gynecology, School of
Medicine, Turgut €Ozal University, Ciftlik Street, Number 57 06510, Emek, Ankara,
Turkey.
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1028-4559/Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. PublishedThe patient's obstetrical history consisted of two pregnancies
resulting in two normal vaginal deliveries. She reported no epi-
sodes of skin lesions during pregnancy or during the breast-feeding
period. Pelvic examination and ultrasound assessment were
essentially normal. Following the diagnosis of APD, initiation of
appropriate treatment was planned. The patient was informed
about treatment options and possible side effects. She received four
weekly intramuscular injections (depot) of the gonadotropin-
releasing hormone (GnRH) analog Lucrin (3.75 mg leuprolide ace-
tate; Abbott, Istanbul, Turkey). Her symptoms improved dramati-
cally within 1 month. She continued with this treatment for 3
months. She hadmild hot ﬂashes, but felt that these were tolerable.
Two months after cessation of therapy, she still had no skin lesions.
A 30-year-old virgin woman was admitted to the gynecology
clinic with complaints of hypomenorrhea, frequent menstruation
(25-day cycles), and hirsutism. She had also experienced herpetic
lesions during every menstrual period for the last 5 years. The pa-
tient noted that the lesions began at the age of 25 and usually
appeared on her face near the lips. She had thought that these le-
sions were herpes and occurred because of stress. Her pelvic ex-
amination and ultrasound assessment were normal. For the skin
lesions, she was referred to a dermatology specialist. Her physical
examination revealed round, hyperpigmented lesions on the left
cheek andover the lips. Complete blood count, urea andelectrolytes,
liver function, fasting glucose levels, and herpes simplex virus 1 and
2 antibodies test results were all normal. Allergy skin testing was
performed with progesterone (50 mg/mL) in normal saline and the
result was positive. Because the patient complained of frequent
menstruation and hirsutism, her gynecologist recommended com-
bined oral contraceptive (COC) therapy with 30 mg of ethinyl estra-
diol and 0.15 mg of levonorgestrel. Subsequently, her skin lesions
resolved completely.
A 24-year-old woman was admitted to the gynecology clinic for
an annual control. She had cyclic eczematous eruptions that
occurred 1 year gynecologic after menarche. She had no signiﬁcant
medical history. She was referred to a dermatology clinic for the
treatment ofmonthly skin lesions. The lesions occurred about 5 days
before menses and disappeared 1e2 days after the menstruation
ceased. Physical examination revealed several erythematous mac-
ules and patches on the pretibial areas, forearms, elbows, andby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Edema of the face with urticarial appearance.
Fig. 2. Intradermal testing with progesterone.
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ment 2 years previously, but this treatment had not improved her
symptoms. Skin prick tests were negative for representative
inhalant allergens. Intradermal testing with progesterone (50 mg/
mL) conﬁrmed the clinical diagnosis with a positive immediateTable 1
Reports of APD patients published in the last 3 years.
Case Age (y) Appearance Loca
Lahmam Bennani et al [8] 23 Pruritic papular-vesicular eruption Trun
George and Badawy [9] 38 Erythema multiforme, urticaria
Le and Wood [10] 34 Papular and eczematous eruption Inne
b
Toms-Whittle et al [11] 34 Pruritic eruption Legs
Lee et al [1] 48 Eczematous eruption Legs
a
García-Ortega and Scorza [12] 35 Generalized erythematous pruritic
wheals, and areas of edema
Face
Medeiros et al [13] 42 Multiple pruritic and erythematous
papules and plaques with crusted
erosions
Face
tr
APD ¼ autoimmune progesterone dermatitis; COC ¼ combined oral contraceptive; GnRHresponse. Following the diagnosis, the patient received COC therapy
with drospirenone (3mg) and ethinyl estradiol (0.02mg). Following
the treatment, no recurrences of the skin lesions occurred, but she
complained of a slight eruption in the arm in the region where al-
lergy testingwas performed during every premenstrual period. The
eruption was treated with an antihistamine gel.
APD was ﬁrst described in 1921 with acute urticarial lesions
during the premenstrual period [3], and since then approximately
70 cases have been published in the international literature. The
earliest age reported has been during menarche [4]. In general, it is
seen in the third decade of life [5] and in ovulatory women. How-
ever, it has also been reported in postmenopausal women receiving
hormone replacement therapy [6] and raloxifene [7]. Table 1 pre-
sents the reports on APD patients published in the last 3 years
[1,8e13].
The morphology of these lesions is variable and includes ery-
thema multiforme, urticaria, eczematous patches, angioedema,
papulopustular/papulovesicular lesions, stomatitis, folliculitis, Ste-
venseJohnson syndrome, vesiculobullous reactions, dermatitis
herpetiformis-like rash, and mucosal lesions [2]. The lesions can be
localized or generalized, and are most commonly found on the face,
but have also been reported on the body, hands, and mucosa of the
oropharynx. Vulvovaginal APD has also been reported as well [14].
Symptoms correlate with progesterone levels and occur during
the luteal phase of the menstrual cycle [15] and resolve 1e2 days
after menstruation. The pathogenesis of APD is unknown. It may
occur inwomenwith a previous history of exogenous progesterone
intake, suggesting that synthetic progesterone may induce a cross-
reaction against the endogenous hormone, or rarely with exposure
to endogenous progesterone during menarche or pregnancy as an
autoimmune reaction [16].
The diagnosis is made with appropriate clinical history as well as
conﬁrmation with an intradermal skin test to progesterone [9],
intramuscular andoral challengewithprogesterone [16], or detection
of circulating antibodies to progesterone. In many cases detection of
antibodies to progesterone has been reported to be negative, and
therefore this is not essential for making a diagnosis [14]. The other
criterion for diagnosing APD is prevention of progesterone-induced
skin eruption by inhibiting ovulation [7]. APD should be differenti-
ated from recurrent eczemas. Differential diagnosis and treatment of
recurrent eczema are presented in Table 2 [17].
APD is caused by a reaction to the endogenous production of
progesterone, and thus treatmentmodalities are generally based on
drugs that suppress ovulation. Antihistamine therapy is usually
unsuccessful and high doses of steroids are needed to suppress
symptoms [1]. At present, the ﬁrst-line therapy is COC. Other
medical options are GnRH analogs, tamoxifen, danazol, and con-
jugated estrogens. Because of the adverse side effects of theselization Duration Intradermal
test
Therapy
k Since puberty þ COC
1 y after menarche  COC
r forearms and
ilateral palms
2 y  Topical steroid
8 y  GnRH analog
, forearms,
nd buttocks
6 y þ GnRH analog
and limbs 7 y þ With pregnancy near
clearance of the lesions
, neckline area,
unk, and limbs
Onset during
pregnancy (5 y)
þ Unresponsive to medical
treatment
Oophorectomy
¼ gonadotropin-releasing hormone.
Table 2
Differential diagnoses and treatment of recurrent eczema.a
Diagnosis Description (clinical features) Treatment
Allergic contact dermatitis A hypersensitivity reaction exists after sensitization to
speciﬁc substances in areas exposed directly to the allergen.
Contact dermatitis is an erythematous, papular dermatitis,
often with areas of vesiculation. Localization may suggest
this diagnosis, but patch tests are needed to deﬁnitely
establish it.
 Corticosteroids: Topical/systemic
 Topical immunomodulators [calcineurin inhibitors
(pimecrolimus and tacrolimus)]
 Phototherapy
 Immunosuppressive agents
 Oral antihistamines
Irritant contact dermatitis Nonspeciﬁc response of the skin to direct irritants (e.g.,
soaps and detergents). It is manifested by erythema, mild
edema, and scaling. The hands are the most important
location.
 Removal of any potential causal agents
 Use of ceramide creams or bland emollients and bland
barrier creams
 Topical corticosteroids
Angioedema Angioedema typically affects the skin andmucosal tissues of
the face, lips, and mouth; however, angioedema may affect
other parts of the body, including respiratory and
gastrointestinal mucosa. It may occur in isolation,
accompanied by urticaria, or as a component of anaphylaxis.
 Second-generation antihistamines
 Systemic corticosteroids
 Fresh frozen plasma, antiﬁbrinolytics, C1 esterase
inhibitor
 Immunosuppressants such as calcineurin inhibitors
Drug eruptions The morphologies of drug eruptions are numerous and
include morbilliform, urticarial, papulosquamous, pustular,
and bullous. Pruritus and dysesthesia without an obvious
eruption can also be seen. These dermatoses may or may
not be pruritic.
 Discontinue the medication if possible
 Systemic antihistamines
 Topical corticosteroids
 Intravenous immunoglobulin
 Cyclosporine
Insect bites After insect bites, secondary eczematous lesions may
develop in the area of the bites, especially on the limbs, and
may be confused with atopic dermatitis.
 Removal of the bee stinger, compress, applying ice packs
 Epinephrine
 Systemic antihistamines
 Systemic corticosteroids
a Adapted from Fitzpatrick's dermatology in general medicine.
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to medical treatment, bilateral oophorectomy is recommended;
however, this is only for those who no longer desire fertility [13]. In
some patients, the disorder completely resolves spontaneously [5].
Other therapeutic agents, such as azathioprine, hydroxy-
chloroquine, dapsone, or cyclosporine, have also been described in
the literature. However, their use is limited because they appear
ineffective or have signiﬁcant side effects [18].
In our cases, treatment with the GnRH analog and COC pills was
effective. The long-term use of GnRH analogs induces some side
effects, and therefore we prescribed the drug for only 3 months.
Symptoms disappeared with the treatment in all the cases. Two
months after cessation of therapy, the patients still had no skin
lesions.
In conclusion, APD is a rare autoimmune response to endoge-
nous progesterone seen 3e10 days before the onset of menstrua-
tion, when progesterone levels are elevated. It can present in
different morphological forms. Premenstrual ﬂare, positive intra-
dermal skin test with progesterone, and prevention of lesions with
inhibition of ovulation are the main criteria for the diagnosis of
APD. There are different treatment modalities and they generate
variable response in affected patients.Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.References
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